OVER 52,000+ SATISFIED CUSTOMERS
November 29, 2023
Studies indicate that individuals with Atopic Dermatitis (AD) possess a distinct skin microbiome compared to those with healthy skin. AD patients often show an overabundance of pathogenic bacteria, such as Staphylococcus aureus, and lower levels of beneficial commensal bacteria like Roseomonas mucosa.
Roseomonas mucosa naturally balances S. aureus in healthy individuals
Commensal microbes play a crucial role in safeguarding and enhancing our skin's health. They form a formidable defense against infections, and healthy individuals have a higher abundance of these protective microbes on their skin, emphasizing their role in maintaining skin integrity.
Pathogenic microbes like Staphylococcus aureus, known for attacking and weakening the skin barrier, can exacerbate AD flare-ups and lead to serious infections. Understanding the impact of these microbes is crucial in managing eczema symptoms.
Dr. Ian A. Myles, an esteemed immunologist, conducted a proof-of-concept study where individuals with AD received Roseomonas mucosa from healthy skin. Visible improvements in skin symptoms were observed, suggesting that restoring healthy bacteria could be a promising treatment approach for eczema.
Research showed that Roseomonas mucosa from healthy skin has the ability to inhibit Staphylococcus aureus and enhance eczema markers and outcomes. This finding highlights the potential of targeting specific bacteria to improve eczema conditions.
Further research indicated that the effects of Roseomonas mucosa on inhibiting S. aureus and enhancing eczema outcomes were observed not only in humans but also in mice and human cells. Understanding these cross-species effects can contribute to the development of effective eczema treatments.
When Roseomonas mucosa was taken from AD patients, it produced irritants instead of the beneficial lipids observed in the bacteria from healthy skin. This highlights the importance of identifying and utilizing the right microbial strains for eczema treatment.
The groundbreaking findings from the studies suggest that restoring healthy bacteria, particularly Roseomonas mucosa, could be a new and innovative approach to treating eczema. Understanding the microbiome's role opens doors to potential breakthroughs in eczema management.
In fact, other researchers at UC San Diego are studying S. hominis with Dr. Richard Gallo. Their study investigated the safety and mechanisms of action of Staphylococcus hominis A9, a bacterium isolated from healthy human skin, as another topical therapy for AD.
In a future article we may discuss the differences between these two bacteria and their safety and efficacy profiles. Please comment below and let us know if you're interested in us sharing that additional information.
Comments will be approved before showing up.